Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents
Clinical & Experimental Allergy2019Vol. 49(10), pp. 1328–1341
Citations Over TimeTop 10% of 2019 papers
Josef Brändström, Mirja Vetander, Ann‐Charlotte Sundqvist, G. Lilja, S. G. O. Johansson, Erik Melén, Eva Sverremark‐Ekström, Anna Nopp, Caroline Nilsson
Abstract
ClinicalTrials.gov; NCT02402231. EudraCT; 2012-005625-78.
Related Papers
- → Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence(2021)136 cited
- → IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms(2022)51 cited
- → Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab(2014)20 cited
- → In response to dosing omalizumab in allergic asthma(2007)5 cited
- → Anti-immunoglobulin E (IgE) Therapy(2016)